If you aren’t a long-time BiotechDueDiligence blog reader or Chimera Research Group subscriber, you may wonder what one of our updates from biotech investor conferences and quarterly earnings conference calls looks like. These reports are not a detailed thesis about the company, nor do they purport to summarize everything the company said on the webcast. […]
OGXI – Oncogenex and Teva finally chart a path forward in NSCLC
The collaboration between Teva Pharma $TEVA and Oncogenex $OGXI for the development of custirsen (aka OGX-011, an antisense against clusterin, licensed from Isis Pharma $ISIS) was always envisioned to include three phase 3 trials, two in prostate cancer and one in non-small cell lung cancer. As I have been chronicling, there have been many false starts […]
Updates from the Leerink Swann Global Healthcare Conference
The annual Leerink Swann Global Healthcare Conference was held February 15-16th, 2012. Several companies that I follow for BiotechDueDiligence and Chimera Research Group presented, and I will summarize the highlights below. Isis Pharmaceutical $ISIS (Archived Chimera content – Pipeline Notes) KYNAMRO (mipomersen) Genzyme/Sanofi are preparing for launch this year. EU application was filed July 2011. […]
ISIS – Research & Development Day Pipeline Recap
Isis Pharma $ISIS held its annual research and development pipeline update for analysts and investors on January 5, 2012. Unfortunately there was no question and answer session, but I’ll review some of the highlights from the two hours of prepared remarks below. An overview of 2012 goals and milestones for the entire antisense pipeline was […]
